A Study of PCSK9 Inhibitor AK102 in Patients With Hypercholesterolemia
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 262 participants.
Also called NCT04358432
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 262 participants
- Sponsor
- Registry
-
NCT04358432
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT04358432. Randomized; triple masking; primary purpose treatment. Start 2020-05-13 (actual); primary completion 2021-02-25 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of PCSK9 Inhibitor AK102 in Patients With Hypercholesterolemia
- Condition
- Hypercholesterolemia
- Intervention (Drug)
- AK102
- Intervention (Drug)
- Placebos
- Intervention (Drug)
- Statins and/or Ezetimibe
- Lead sponsor
- Akeso
- Collaborator
- AD Pharmaceuticals Co., Ltd.
Record details
- Record id
cardio:ct-nct04358432- Content hash
3c48bffdf8135c7fd6fb9fbb310494792855b409e9788df57a26a30cc712b228